Table 3.
Proportion of patients with “good”, “moderate”, and “poor” levels of functioning at baseline and last observation, by treatment group
| Visit/functioning cluster | Olanzapine-LAI | Oral olanzapine | Total | Pa |
|---|---|---|---|---|
| Baseline, n (%) | 0.11 | |||
| “Good” | 50 (19.2) | 37 (14.2) | 87 | |
| “Moderate” | 150 (57.5) | 172 (66.2) | 322 | |
| “Poor” | 61 (23.4) | 51 (19.6) | 112 | |
| 2 years, n (%) | 0.26 | |||
| “Good” | 66 (27.5) | 56 (24.5) | 122 | |
| “Moderate” | 125 (52.1) | 136 (59.4) | 261 | |
| “Poor” | 49 (20.4) | 37 (16.2) | 86 |
Note:
a
P value comparing the proportion of patients in each cluster between olanzapine-LAI and oral olanzapine.
Abbreviation: LAI, long-acting injection.